New Treatment Options for DLBCL: Impact on Sequencing Therapeutic Choices : Episode 9

Opinion

Video

February 6, 2024

Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL

Author(s):

Clinical Oncologists focus their discussion on navigating toxicities specific to CAR T, highlighting cytokine release syndrome (CRS) and neurotoxicities.

EP: 1.Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma

EP: 2.Evolving Practice Standards and Disease Progression Beyond Frontline Therapy for Patients with DLBCL

EP: 3.Treatment Selection in Second Line R/R DLBCL

EP: 4.Tafasitamab and Lenalidomide for R/R DLBCL

EP: 5.Real-World Outcomes of Tafasitamab-Lenalidomide for Patients with R/R DLBCL

EP: 6.The Role of CAR T-Cell Therapy in R/R DLBCL

EP: 7.Data Updates: CAR T in the ZUMA-7 and TRANSFORM Trials for R/R DLBCL

EP: 8.Clinical Perspectives of CAR T in R/R Diffuse Large B-Cell Lymphoma

Now Viewing

EP: 9.Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL

EP: 10.Relapsed/Refractory DLBCL: Therapeutic Options in the Third Line Setting

EP: 11.Bispecifics for Third Line Therapy of R/R DLBCL

EP: 12.R/R DLBCL: Safety Considerations for Bispecific Antibodies

EP: 13.Treatment Sequencing of Later Line Therapies in R/R DLBCL

EP: 14.Additional Data Updates from ASH 2023

EP: 15.Future Outlooks in the Treatment of R/R DLBCL

Related Content

November 15th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

November 14th 2024

FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML

November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Jennifer Amengual, MD, Herbert Irving Assistant Professor of Medicine, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center

November 13th 2024

Real-World Experience With CAR T Varies From Trials in DLBCL

Revumenib in NPM1+ R/R AML | Image Credit: © LASZLO– stock.adobe.com

November 12th 2024

Revumenib Meets CR/CRh End Point in NPM1+ R/R AML